Proteolysis Targeting Chimeras in Non-Small Cell Lung Cancer
Lung cancer is the most common cause of cancer-related deaths globally. [1] The majority of non-small cell lung cancer ’s (NSCLC) are diagnosed in advanced stages. [2] Historically, the prognosis of NSCLC has been very poor; However, the development of targeted therapies has greatly improved survival. Targeted therapies are more efficacious compared to chemotherapy and have fewer side effects. As a result, the ini tial evaluation of most cancers involves collection of molecular and genetic data. The use of targeted therapies has become prominent in NSCLC since the advent of the first epidermal growth factor (EGFR) tyrosine kinase inhibitors (TKI).
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Garo Hagopian, Christopher Grant, Misako Nagasaka Tags: Anti-tumour Treatment Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Genetics | Grants | Lung Cancer | Non-Small Cell Lung Cancer